{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:51Z","timestamp":1792513071557,"version":"4.5.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.alit.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T20:01:53Z","timestamp":1749585713000},"page":"345-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Recent advances in the diagnosis and treatment of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-856X","authenticated-orcid":false,"given":"Yuko","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-7062","authenticated-orcid":false,"given":"Natsumi","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2025.05.008_bib1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.05.008_bib2","doi-asserted-by":"crossref","first-page":"1213889","DOI":"10.3389\/fmed.2023.1213889","article-title":"Updates in SJS\/TEN: collaboration, innovation, and community","volume":"10","author":"Marks","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.alit.2025.05.008_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Aihara","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib5","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.05.008_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1071","article-title":"The medication risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Asians: the major drug causality and comparison with the US FDA label","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.alit.2025.05.008_bib7","doi-asserted-by":"crossref","first-page":"949520","DOI":"10.3389\/fmed.2022.949520","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.alit.2025.05.008_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.alit.2025.05.008_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.alit.2025.05.008_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.alit.2025.05.008_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau","year":"1997","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib12","first-page":"6","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jdermsci.2020.09.009","article-title":"The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018","volume":"100","author":"Sunaga","year":"2020","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.alit.2025.05.008_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States Adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib15","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using National Health Insurance Database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.alit.2025.05.008_bib16","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198582","article-title":"Life-threatening dermatoses: Stevens-Johnson syndrome and toxic epidermal necrolysis. Impact on the Spanish public health system (2010-2015)","volume":"13","author":"Velasco-Tirado","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.alit.2025.05.008_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/pds.3937","article-title":"Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry","volume":"25","author":"Diphoorn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.alit.2025.05.008_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.110749","article-title":"A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population","volume":"79","author":"Patel","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.alit.2025.05.008_bib20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s13555-024-01180-6","article-title":"Evaluation of the factors influencing mortality in patients with Stevens-Johnson syndrome and tsoxic epidermal necrolysis: a multicenter study of 166 patients","volume":"14","author":"Erduran","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.alit.2025.05.008_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.100936","article-title":"The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions","volume":"17","author":"James","year":"2024","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.alit.2025.05.008_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2295","article-title":"Long-term sequelae of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"96","author":"Yang","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajo.2024.05.011","article-title":"Improvement of the ocular prognosis of Stevens-Johnson syndrome and toxic epidermal necrolysis: a national survey in Japan","volume":"267","author":"Kojima","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2025.05.008_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jdin.2022.12.002","article-title":"Risk factors and drugs that trigger the onset of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a population-based cohort study using the Shizuoka Kokuho database","volume":"11","author":"Ubukata","year":"2023","journal-title":"JAAD Int"},{"key":"10.1016\/j.alit.2025.05.008_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.17039","article-title":"Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications","volume":"51","author":"Satoh","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/1346-8138.16476","article-title":"Clinical features and outcomes in children with STEVENS\u2013JOHNSON syndrome and toxic epidermal necrolysis","volume":"49","author":"Chi","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.alit.2025.05.008_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/ped.13613","article-title":"Clinical features of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"60","author":"Sato","year":"2018","journal-title":"Pediatr Int"},{"key":"10.1016\/j.alit.2025.05.008_bib31","first-page":"52","article-title":"Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"90","author":"Liotti","year":"2019","journal-title":"Acta Bio Med Atenei Parm"},{"key":"10.1016\/j.alit.2025.05.008_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1684\/ejd.2011.1510","article-title":"Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN)","volume":"21","author":"Watanabe","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib33","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/CCM.0b013e31821201ed","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review","volume":"39","author":"Gerull","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.alit.2025.05.008_bib34","article-title":"Efficacy of continuous intravenous fentanyl for oral mucosal pain in Stevens-Johnson syndrome: a case report","volume":"16","author":"Ito","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.alit.2025.05.008_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7599\/hmr.2016.36.3.174","article-title":"Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"36","author":"Kang","year":"2016","journal-title":"Hanyang Med Rev"},{"key":"10.1016\/j.alit.2025.05.008_bib36","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s40123-023-00725-w","article-title":"Ophthalmic aspects of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a narrative review","volume":"12","author":"T\u00f3th","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.alit.2025.05.008_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1083-3188(02)00146-8","article-title":"Vaginal adhesions caused by Stevens-Johnson syndrome","volume":"15","author":"Hart","year":"2002","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.alit.2025.05.008_bib38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archotol.124.12.1375","article-title":"Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis","volume":"124","author":"Barrera","year":"1998","journal-title":"Arch Otolaryngol Neck Surg"},{"key":"10.1016\/j.alit.2025.05.008_bib39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.ijporl.2014.03.037","article-title":"Otologic complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"78","author":"Hotaling","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.alit.2025.05.008_bib40","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.burns.2019.09.006","article-title":"Upper airway involvement in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"46","author":"Bhullar","year":"2020","journal-title":"Burns"},{"key":"10.1016\/j.alit.2025.05.008_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.6294","article-title":"Acetaminophen-induced Stevens\u2013Johnson syndrome with lethal lung injury: a case report","volume":"10","author":"Nakamura","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.alit.2025.05.008_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1346-8138.2006.00142.x","article-title":"Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro\/SS-A and a review of the published work","volume":"33","author":"Kamada","year":"2006","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib43","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0022-3468(87)80492-X","article-title":"Esophageal stricture secondary to Stevens-Johnson syndrome","volume":"22","author":"Howell","year":"1987","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.alit.2025.05.008_bib44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/CEG.S269349","article-title":"Severe gastrointestinal involvement in pediatric Stevens-Johnson syndrome: a case report and review of the literature","volume":"13","author":"Bechek","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.alit.2025.05.008_bib45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000195632","article-title":"Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"29","author":"Hung","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.alit.2025.05.008_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2013.03.024","article-title":"Characteristics of liver injury in drug-induced systemic hypersensitivity reactions","volume":"69","author":"Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib47","first-page":"547","article-title":"Erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis \u2013 diagnosis and treatment","volume":"18","author":"Gr\u00fcnwald","year":"2020","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"10.1016\/j.alit.2025.05.008_bib48","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.1995.01690230046008","article-title":"Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome","volume":"131","author":"C\u00f4t\u00e9","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4065\/mcp.2009.0379","article-title":"Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic","volume":"85","author":"Wetter","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.alit.2025.05.008_bib50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0560.1995.tb01420.x","article-title":"Toxic epidermal necrolysis: a study of the sweat glands","volume":"22","author":"Akosa","year":"1995","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.alit.2025.05.008_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1346-8138.2009.00746.x","article-title":"Erythema multiforme, Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis","volume":"37","author":"Hosaka","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/jdv.19424","article-title":"Fast, bedside diagnosis of toxic epidermal necrolysis using ex vivo confocal laser scanning microscopy: a retrospective study","volume":"38","author":"Tonellotto","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib53","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-4632.2011.05348.x","article-title":"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist","volume":"51","author":"Sokumbi","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib54","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2019.05.061","article-title":"Distinguishing Stevens-Johnson syndrome\/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation\u2014a retrospective chart review","volume":"81","author":"Weinkle","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bcp.13827","article-title":"Drug-induced linear immunoglobulin A bullous dermatosis: a French retrospective pharmacovigilance study of 69 cases","volume":"85","author":"Garel","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.alit.2025.05.008_bib56","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1111\/jdv.14935","article-title":"Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that \u2018toxic\u2019 epidermal necrolysis can be \u2018non-toxic\u2019","volume":"32","author":"Dumas","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/pde.15069","article-title":"Toxic epidermal necrolysis-like acute graft-versus-host disease in pediatric bone marrow transplant patients: case series and review of the literature","volume":"39","author":"Sheu Song","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib58","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0190-9622(82)70114-8","article-title":"Toxic shock syndrome or toxic epidermal necrolysis","volume":"7","author":"Hurwitz","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib59","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1093\/oncolo\/oyac170","article-title":"Regarding \u201cmanagement of dermatologic events associated with the nectin-4\u2013directed antibody-drug conjugate enfortumab vedotin.\u201d","volume":"27","author":"Ingen-Housz-Oro","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.alit.2025.05.008_bib60","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/DAD.0000000000002255","article-title":"Enfortumab vedotin\u2013associated toxic epidermal necrolysis-like toxic erythema of chemotherapy","volume":"44","author":"Birmingham","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.alit.2025.05.008_bib61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2023.10.025","article-title":"Enfortumab vedotin toxic epidermal necrolysis\u2013like blistering dermatosis: a case series and review of the literature","volume":"43","author":"Khanjar","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.alit.2025.05.008_bib62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cup.14689","article-title":"Enfortumab vedotin-induced cutaneous eruption: ring mitotic figures as a distinctive histopathologic feature","volume":"51","author":"Sport","year":"2024","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.alit.2025.05.008_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment","volume":"192","author":"Hama","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Fouchard","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib65","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib66","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1468-3083.2012.04502.x","article-title":"SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population","volume":"27","author":"Hu","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib67","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/ijd.12466","article-title":"A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of toxic epidermal necrolysis","volume":"54","author":"Bansal","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.alit.2025.05.008_bib69","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.BCR.0000216532.71360.9B","article-title":"SCORTEN overestimates mortality in the setting of a standardized treatment protocol","volume":"27","author":"Imahara","year":"2006","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.alit.2025.05.008_bib70","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jbcr\/irx016","article-title":"How does SCORTEN score?","volume":"39","author":"Zavala","year":"2018","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.alit.2025.05.008_bib71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12911-022-02013-2","article-title":"Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis","volume":"22","author":"Stru\u017cyna","year":"2022","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.alit.2025.05.008_bib72","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/jdv.16137","article-title":"Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"34","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib73","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jbcr\/irae140","article-title":"Utility of the severity-of-illness score for toxic epidermal necrolysis (SCORTEN) in pediatric Stevens-Johnson syndrome patients","volume":"46","author":"Gust","year":"2025","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.alit.2025.05.008_bib74","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/ijd.17529","article-title":"Systematic review and meta-analysis of non-SCORTEN predictors of mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"202","author":"Stewart","year":"2025","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib75","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jamadermatol.2021.5119","article-title":"Improvement of mortality prognostication in patients with epidermal necrolysis: the role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)","volume":"158","author":"Koh","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib76","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2014ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib77","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaad.2021.04.082","article-title":"Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"85","author":"Duplisea","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib78","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/1346-8138.15490","article-title":"Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"47","author":"Torres-Navarro","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib79","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib80","first-page":"e514","article-title":"Comparison of performance of SCORTEN, ABCD-10 and RE-SCORTEN in a cohort of patients with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"202","author":"Hsieh","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/medicina61010066","article-title":"Epidemiological characteristics and prognostic scoring in toxic epidermal necrolysis and Stevens\u2013Johnson syndrome: insights from a 17-year burn center experience","volume":"61","author":"Breidung","year":"2025","journal-title":"Medicina (Mex)"},{"key":"10.1016\/j.alit.2025.05.008_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaip.2023.07.001","article-title":"Development and validation of a novel score to predict mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis: CRISTEN","volume":"11","author":"Hama","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.05.008_bib83","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","article-title":"Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study","volume":"32","author":"Sekula","year":"2011","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.alit.2025.05.008_bib84","first-page":"CD013130","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.alit.2025.05.008_bib85","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib86","first-page":"1637","article-title":"[The Japanese Dermatological association guidelines for the management of SJS\/TEN]","volume":"126","author":"Shiohara","year":"2016","journal-title":"Jpn J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib87","first-page":"701","article-title":"[The Japanese Dermatological association guidelines for the management of SJS\/TEN 2024 addendum]","volume":"135","author":"Watanabe","year":"2025","journal-title":"Jpn J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib88","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijd.IJD_583_17","article-title":"Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines","volume":"63","author":"Kumar","year":"2018","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319894469","article-title":"Multidisciplinary care in Stevens-Johnson syndrome","volume":"11","author":"Shanbhag","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.alit.2025.05.008_bib91","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/BCR.0000000000000329","article-title":"Predicting mechanical ventilation and mortality: early and late indicators in Steven\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"37","author":"Beck","year":"2016","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.alit.2025.05.008_bib92","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib93","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaad.2020.02.066","article-title":"Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults","volume":"82","author":"Seminario-Vidal","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib94","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdermsci.2022.07.004","article-title":"Risk factors for sepsis and effects of pretreatment with systemic steroid therapy for underlying condition in SJS\/TEN patients: results of a nationwide cross-sectional survey in 489 Japanese patients","volume":"107","author":"Sunaga","year":"2022","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.alit.2025.05.008_bib95","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjd.19893","article-title":"Supportive care in the acute phase of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus","volume":"185","author":"Br\u00fcggen","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib96","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib97","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bjd.17267","article-title":"Post-traumatic stress disorder in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients","volume":"180","author":"Hefez","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib98","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a Pan-European multicenter study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00006454-198205000-00005","article-title":"Stevens-Johnson syndrome in children","volume":"1","author":"Ginsburg","year":"1982","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.alit.2025.05.008_bib100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.alit.2025.05.008_bib101","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.alit.2025.05.008_bib102","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib103","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.12968\/jowc.2021.30.12.1012","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"30","author":"Houschyar","year":"2021","journal-title":"J Wound Care"},{"key":"10.1016\/j.alit.2025.05.008_bib104","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib105","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ijd.13379","article-title":"A retrospective analysis of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids","volume":"55","author":"Liu","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib106","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis: efficacy of IVIg for TEN","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750173","article-title":"Intravenous immunoglobulin combined with corticosteroids for the treatment of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: a propensity-matched retrospective study in China","volume":"12","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.alit.2025.05.008_bib108","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2025.05.008_bib109","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2021.06.015","article-title":"Corticosteroid pulse therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis patients with acute ocular involvement","volume":"231","author":"Mieno","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2025.05.008_bib111","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12758","article-title":"Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"32","author":"Gilbert","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.alit.2025.05.008_bib112","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib113","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib114","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: ciclosporin for SJS and TEN","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Ar\u00e9valo","year":"2000","journal-title":"J Trauma Inj Infect Crit Care"},{"key":"10.1016\/j.alit.2025.05.008_bib116","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.alit.2025.05.008_bib117","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/jdv.16685","article-title":"Systemic therapies for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a SCORTEN-based systematic review and meta-analysis","volume":"35","author":"Torres-Navarro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib118","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients\u2014exposed\/unexposed and propensity score-matched analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib119","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jid.2018.03.1496","article-title":"Selective use of cyclosporine for Stevens-Johnson syndrome\/toxic epidermal necrolysis may exclude patients with poor prognostic factors","volume":"138","author":"Noe","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib120","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jdv.16339","article-title":"Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)","volume":"34","author":"Kuijper","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.008_bib121","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis: cytokines and chemokine receptors in EM and SJS\/TEN","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib122","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2025.05.008_bib123","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.05.008_bib124","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.alit.2025.05.008_bib125","first-page":"229","article-title":"Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin. G","volume":"143","author":"Romanelli","year":"2008","journal-title":"Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr"},{"key":"10.1016\/j.alit.2025.05.008_bib126","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3899\/jrheum.111123","article-title":"Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease","volume":"39","author":"Bayry","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.alit.2025.05.008_bib127","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib128","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijd.12423","article-title":"Intravenous immunoglobulin in the treatment of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies","volume":"54","author":"Barron","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib130","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","article-title":"Toxic epidermal necrolysis: five years of treatment experience from a burn unit","volume":"67","author":"Firoz","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib131","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clindermatol.2009.06.020","article-title":"Severe cutaneous adverse drug reactions: who should treat, where and how?: facts and controversies","volume":"28","author":"Wolf","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib132","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00128071-200607060-00004","article-title":"Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"7","author":"Mittmann","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib133","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1423-0410.2008.001036.x","article-title":"Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin","volume":"94","author":"Reipert","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.alit.2025.05.008_bib134","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcrc.2017.07.002","article-title":"Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study","volume":"42","author":"Han","year":"2017","journal-title":"J Crit Care"},{"key":"10.1016\/j.alit.2025.05.008_bib136","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamadermatol.2023.0035","article-title":"Evaluation of plasmapheresis vs immunoglobulin as first treatment after ineffective systemic corticosteroid therapy for patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"159","author":"Miyamoto","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.008_bib139","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","article-title":"Spatial proteomics identifies JAKi as treatment for a lethal skin disease","volume":"635","author":"Nordmann","year":"2024","journal-title":"Nature"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:17:38Z","timestamp":1750979858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893025000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1323893025000589"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2025.05.008","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the diagnosis and treatment of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}